Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY26 results Revenue from Operations: Rs 551.7 crore compared to Rs 502.4 crore during Q1FY25, change 9.8%. EBITDA: Rs 69.5 crore compared to Rs 58.2 crore during Q1FY25, change 19.5%. EBITDA Margin: 12.4% for Q1FY26. PAT: Rs 34.0 crore compared to Rs 29.7 crore during Q1FY25, change 14.4%. PAT Margin: 6.1% for Q1FY26. Vikas Gupta, Joint Managing Director, said: “We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, with several key product prices having bottomed out, IOL has delivered impressive performance, underscoring the resilience of our integrated business model. Our continued focus on portfolio diversification is yielding results, with non-Ibuprofen APIs gaining traction across global markets. With the commissioning of our fully backwardintegrated Paracetamol production unit, we are increasing our presence in both regulated and non-regulated markets. This positions us well to capture emerging opportunities, especially in regions where quality and compliance remain key differentiators. In the chemicals segment, the successful REACH registration of Acetic Anhydride under EU norms opens up new growth avenues in Europe, reinforcing our commitment to global standards and market expansion. As we move forward, our priorities remain clear — to scale high-value APIs, deepen our export footprint, and drive operational excellence. With a robust balance sheet and a strong innovation pipeline, we are confident in our ability to deliver sustainable growth and long-term value for all stakeholders.” Result PDF